Arkolith/Insider Trading/NKTR/Form 4

Zalevsky Jonathan

Chief R&D OfficerNEKTAR THERAPEUTICS (NKTR) · full profile →Form 4 · filed Sep 8, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$58K
Net Open-Market Flow
-$58K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 4, 2025Sell(S)307$35.69$11K17K
Sep 4, 2025Sell(S)189$34.41$7K18K
Sep 4, 2025Sell(S)793$32.43$26K18K
Sep 4, 2025Sell(S)432$33.60$15K18K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-113692) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML